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Physiology and Pharmacology
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PURPOSE. The neonatal Fc receptor (FcRn) plays a critical role in the homeostasis and
degradation of immunoglobulin G (IgG). It mediates the transport of IgG across epithelial cell
barriers and recycles IgG in endothelial cells back into the bloodstream. These functions
critically depend on the binding of FcRn to the Fc domain of IgG. The half-life and distribution
of intravitreally injected anti-VEGF molecules containing IgG-Fc domains might therefore be
affected by FcRn expressed in the eye. In order to establish whether FcRn–Fc(IgG)
interactions may occur in the eye, we studied the mRNA and protein distribution of FcRn in
postmortem ocular tissue.
METHODS. We used qPCR to study mRNA expression of the transmembrane chain of FcRn
(FCGRT) in retina, optic nerve, RPE/choroid plexus, ciliary body/iris plexus, lens, cornea, and
conjunctiva isolated from mouse, rat, pig, and human postmortem eyes and used
immunohistochemistry to determine the pattern of FcRn expression in FCGRT-transgenic
mouse and human eyes.
RESULTS. In all four tested species, Fcgrt mRNA was expressed in the retina, RPE/choroid, and
the ciliary body/iris, while immunohistochemistry documented FcRn protein expression in
the ciliary body epithelium, macrophages, and endothelial cells in the retinal and choroidal
vasculature.
CONCLUSIONS. Our results demonstrate that FcRn has the potential to interact with IgG-Fc
domains in the ciliary epithelium and retinal and choroidal vasculature, which might affect
the half-life and distribution of intravitreally injected Fc-carrying molecules.
Keywords: blood-ocular barrier, drug delivery, ciliary epithelium, macrophages
The neonatal Fc receptor (FcRn) is a heterodimer composedof a transmembrane alpha chain (FCGRT) and a soluble
beta chain (beta-2-microglobullin, B2M).1 This heterodimer
plays a critical role in the homeostasis of albumin and
immunoglobulin G (IgG) by regulating intracellular trafficking
of these proteins in epithelial cells, the vascular endothelium,
and inflammatory cells.2–5 The function of FcRn was first
recognized in the neonatal rodent intestine, where it mediates
the transfer of maternal IgG to the newborn.6
In adult physiology, FcRn is important for the maintenance
of albumin and IgG levels in the plasma. This was most
convincingly demonstrated in mice lacking a functional Fcgrt
gene, which had reduced albumin and IgG levels in the plasma
compared with wild-type controls.2 The mechanism of this
protective effect is based on FcRn localized in early endosomes
in endothelial cells. IgG may be incorporated into endothelial
endosomes by nonspecific endocytosis of soluble extracellular
material. The Fc domain of IgG is then bound by FcRn in acidic
early endosomes in a strictly pH-dependent manner.7 This leads
to recycling of the IgG to the cell surface where, facilitated by
neutral pH, IgG is released again. This IgG-Fc specific salvaging
mechanism is the reason why the half-life of IgG in plasma is
greatly extended compared with that of other antibody
classes.8,9 The interest in mechanisms that influence IgG half-
life and transport has been heightened by the emergence of
monoclonal IgG antibodies as useful therapeutic agents.
In the ophthalmic clinic, VEGF-blocking antibodies are
routinely injected into the vitreous. They are effective in halting
the progression of AMD with choroidal neovascularization or
exudative forms of AMDs and in the treatment of exudative
forms of central or branch retinal vein occlusion or thrombosis,
as well as in the treatments of some forms of diabetic
retinopathy edemas, and are currently also in trial for other
eye conditions with vascular complications. However, the
retina is an immune privileged site and immunoglobulins are
normally excluded by the retina-blood-barrier. The high
concentration of IgG after intravitreally injection is therefore
not a naturally occurring situation and the biological mecha-
nisms that affect the fate of intravitreally injected antibodies are
not well understood. The topic is clinically relevant not only for
the therapeutic effects of anti-VEGF antibodies within the eye,
but also for off-target effects in the periphery if anti-VEGF
antibodies are transported from the vitreous into the blood
circulation.
Since FcRn transports IgG across epithelial and endothelial
barriers, it is plausible that FcRn-mediated mechanisms exert
control over the distribution and persistence of intravitreally
injected therapeutic IgG. Defining the cellular patterns of FcRn
expression in the substructures of the eye is therefore clinically
relevant. However, such information is currently limited to a
previous study of rat ocular tissue in which a monoclonal
antibody was used to localize FcRn to the ciliary body and
retinal blood vessels but not to the RPE and choroid.10 Here we
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address this issue more comprehensively by using a combina-
tion of RT-qPCR and immunohistochemistry to define the
patterns of FcRn expression in substructures of the rat, mouse,
pig, and human eyes.
MATERIALS AND METHODS
mRNA Isolation
Tissue samples of unfixed retina, RPE/choroid complex, optic
nerve, iris/ciliary body, lens, cornea, and conjunctiva were
dissected from rats (n¼3); C57BL/6J mice (n¼3); and pig (n¼
3) eyes, and snap-frozen ready for RNA extraction. Three sets
of samples were also dissected from equivalent regions from
two anonymous human eye donors. The human tissue did not
include corneas as these were used for transplantation. Isolated
samples were snap-frozen on dry ice. For mouse endothelial
cell–enriched samples, five mouse retinas were pooled and
enzymatically digested. Endothelial cells were isolated using
magnetic beads (Dynabead; Invitrogen, Carlsbad, CA) as
previously described.11 Isolated endothelial cells and leftover
retinal cells were then snap-frozen. Three independent
experiments were performed and results averaged. For human
RPE enrichment, three separate regions of RPE/choroid
complex were dissected from two donor eyes. The RPE was
separated from the choroid by gently pipetting 50 lL RNase
free PBS over the surface until no RPE cells were left visible
under a dissection microscope. The RPE cells suspended in
PBS and the remaining choroid were then snap-frozen. RNA
was extracted from the collected samples using a commercial
reagent (TRIzol; Sigma-Aldrich, St. Louis, MO) and cDNA was
reverse-transcribed using a reverse transcription kit (Qiagen
QuantiTect; Qiagen, Venlo, Limburg). Three independent
experiments were performed and results averaged.
Quantitative Real-Time PCR (qPCR)
Real-time PCR was performed using a master mix (GoTag
qPCR; Promega, Madison, WI) and the following primer pairs:
1. Rat—b-actin (Actb) F: AAGATCAAGATCATTGCTCCTCC
R: TAACAGTCCGCCTAGAAGCA, Gapdh F: GA
GAAACCTGCCAAGTATGATGAC R: GGGAGTTGCTGTT
GAAGTCAC, CyclophilinA (Ppia) F: CCAAACA
CAAATGGTTCCCAG R: CCCGCAAGTCAAAGAAA
TTAGAG, Fcgrt F: CCAGGTGTCTTGGTATTGGG R:
GTGTGAAGGTCCCATTTATTTGGT;
2. Mouse—Actb F: TCCAAGTATCCATGAAATAAGTGG R:
GCAGTACATAATTTACACAGAAGC, Gapdh F: GA
GAAACCTGCCAAGTATGATGAC R: ATCGAAGGTGGAA
GAGTGGG, Ppia F: ACTTCATCCTAAAGCATACAGGTC
R: CTTGCCATCCAGCCATTCAG, Fcgrt F: AGCT
CAAGTTCCGATTCCTG R: GATCTGGCTGATGAATC
TAGGTC, Cdh5 F: TGGAAACACAAGATGCCCTG R:
TGTATGTGGATTGAGTAAAGACGG;
3. Pig—Actb F: ATCCTGACCCTCAAGTACCC R: AGAGTC
CATGACAATGCCAG, Gapdh F: CATCAAGAAGGTGGT
GAAGCAG R: TTCATTGTCGTACCAGGAAATGAG, Ppia
F: AAGACTGAGTGGTTGGATGG R: AATGGT
GATCTTCTTGCTGGT, Fcgrt F: GTCGTCGCTAACAGTC
AAGAG R: CCACGATCAAGAGCAGTAGGA; and
4. Human—Actb F: CCTGGACTTCGAGCAAGAGATG R:
AGGAAGGAAGGCTGGAAGAGTG, GAPDH F: CATCAA
GAAGGTGGTGAAGCAG R: TTCATTGTCGTACCAG
GAAATGAG, PPIA F: AAGACTGAGTGGTTGGATGG R:
AATGGTGATCTTCTTGCTGGT, FCGRT F: GAAACCTG
GAGTGGAAGGAG R: CGGAGGGTAGAAGGAGAAGG
and RPE65 F: AAGATGATGGTGTAGTTCTGAGTG R:
AAGGTGACAGGGATGTTAATCTC.
Each sample was measured in triplicates in three separate
experiments based on Actb, Gapdh, and Ppia internal controls.
Relative values based on the three different internal controls
were all similar and averaged. Three samples per tissue type
were measured in this way and then averaged.
Tissue for Immunohistochemistry
In the case of mice and rats, whole eyes were removed, placed
in OCT compound, and flash-frozen. Alternatively, the cornea
was pierced and the eyes were fixed in 4% (wt/vol)
paraformaldehyde (PFA, Sigma-Aldrich) in PBS for 1 hour at
room temperature (RT), equilibrated in 30% (wt/vol) sucrose
(Sigma-Aldrich) in PBS, transferred to, and orientated in OCT
compound (Agar Scientific, Essex, UK) and frozen. Mouse
strains used were C57BL/6J, Fcgrt knockout mice B6.Cg-
Fcg r t tm 1D c r (Fcg r t/) , 1 2 and B6 .Cg -Fcg r t tm 1D c r
Tg(FCGRT)32Dcr/DcrJ, which carry a human FCGRT transgene
and lack mouse Fcgrt (hFCGRT transgenic mice).13
Human eyes collected by Moorfields Eye Bank for corneal
transplantation from anonymous donors were dissected to
isolate samples from the ciliary body, iris, lens, and a region of
posterior pole containing optic nerve, parafovea, and temporal
retina. Tissue was either flash-frozen unfixed or alternatively
fixed in 2% (wt/vol) PFA, equilibrated in 30% (wt/vol) sucrose
in PBS and frozen in OCT compound.
Immunohistochemistry
Cryosections (10 lm) were cut from mouse and human
samples, mounted on slides (Superfrost Plus; VWR, Leicester-
shire, UK), and left to dry at RT. Cryosections from unfixed
tissue were fixed in acetone (Sigma-Aldrich) for 10 minutes at
208C prior to further processing. For IBA-1 staining, adjacent
sections from unfixed tissue were fixed with 4% (wt/vol) PFA
for 10 minutes prior to further processing. Sections from PFA-
fixed human tissue required antigen retrieval prior to IHC;
sections were heated to 1108C in a solution of 90% glycerol and
10% 0.01 M citrate buffer, pH 6.0 for 10 minutes. Sections were
then incubated in blocking buffer (1% [wt/vol] bovine serum
albumin, 0.5% [wt/vol] Tween20 in PBS, all reagents from
Sigma-Aldrich) for 1 hour at RT, followed by 1 hour at RT in
primary antibodies diluted in blocking buffer. Sections were
treated in wash buffer (0.5% [wt/vol] Tween20 in PBS) and
incubated in secondary antibody diluted in wash buffer for 1
hour at RT. Sections were then treated with wash buffer,
counter stained with Hoechst, washed with PBS, mounted in
mounting medium (Mowiol 4-88; Merck Millipore, Billerica,
MA) and imaged with a confocal microscope (Zeiss LSM 700;
Carl Zeiss Microscopy, Thornwood, NY).
Primary antibodies used for hFcRn detection were rabbit,
polyclonal anti-FCGRT, Human Protein Atlas14 (HPA)012122
(Sigma-Aldrich); HPA015130 (Sigma-Aldrich); M-255 (sc-66893;
Santa Cruz Biotechnology, Dallas, TX); H-274 (sc-66892, Santa
Cruz Biotechnology); mouse, monoclonal anti-FCGRT, 1G3
(myeloma hybridoma cell line CRL-2434); H-4 (sc-166413;
Santa Cruz Biotechnology); and ADM31.15 Iba-1 antibody
(rabbit) was used as a macrophage marker.16 Secondary
antibodies (Invitrogen) used were goat AlexaFluor 594-
conjugated anti-mouse IgG, donkey AlexaFluor 555-conjugated
anti-rabbit IgG, rabbit anti-mouse IgG, and rabbit anti-Alexa-
Fluor 488. Lectins used were fluorescein conjugated IB4
(Vector Labs, Burlingame, CA) for mouse and fluorescein
conjugated UAE (Sigma-Aldrich) for human tissue. Conjugation
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of antibodies with AlexaFluor 488 was carried out using an
antibody labeling kit (APEX; Invitrogen) according to the
manufacturer’s instructions.
RESULTS
Fcgrt mRNA Expression in the Eye
To assess where in the eye FcRn is present, we used RT-qPCR
to measure Fcgrt mRNA in tissue that had been dissected from
different parts of the eye. Species-specific primers for Fcgrt
from four different species (mouse, rat, pig, and human) were
used. Values were internally normalized against mRNA from
three different housekeeping genes (Actb, Gapdh, and Ppia)
from the same sample. From different species and different
tissue types, three samples each were measured and averaged
(Fig. 1). In the rat eye (Fig. 1A), Fcgrt mRNA was readily
detected in the retina, optic nerve, RPE/choroid, and ciliary
body/iris. Expression in the lens, cornea, and conjunctiva was
much lower. Very similar findings were made in mouse and pig
eyes (Figs. 1B, 1C). In all of these three species expression was
FIGURE 1. Fcgrt mRNA levels in different tissues of the eye measured by RT-qPCR. Values were normalized to 3 internal standards (Actb, Gapdh,
and Ppia) and averaged. (A–D) Measurements in different tissues isolated from rat, mouse, pig, and human eyes (three samples from each tissue in
each species). They have been normalized to retina values. (E) qPCR measurements on dissociated mouse retina after bead-based enrichment of
blood vessel fragments from three independent experiments. The left panel demonstrates enrichment efficiency using an endothelial cell marker
(cadherin 5, also known as VE-Cad) and the right panel shows Fcgrt mRNA levels. (F) Shows in the left panel an RPE-specific marker (RPE65) to
demonstrate efficiency of RPE cell enrichment from human choroid. The right panel shows an enrichment of FCGRT mRNA in the RPE fraction
(three independent experiments). Error bars indicate standard deviations based on the variations between the three samples.
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lowest in the cornea. In human eyes (Fig. 1D), we did not
obtain a sample from the cornea because the postmortem eye
donations we used for our analysis were for the primary
purpose of corneal transplantation. In the other human
samples, we found particularly high expression of FCGRT
mRNA in the RPE/choroid and the ciliary body/iris.
We then applied cell enrichment protocols prior to mRNA
isolation to investigate the cell patterns of Fcgrt expression. To
this end, antibody-coated magnetic beads were used to isolate
endothelial cells from single cell suspensions of mouse retinas.
This resulted in a 60-fold enrichment of mRNA for the
endothelial cell marker cadherin 5 (Cdh5, also known as VE-
cadherin) in the endothelial cell–enriched fraction versus the
remaining endothelial cell–depleted retinal cells (Fig. 1E). Fcgrt
mRNA was also enriched in the endothelial fraction (5-fold),
demonstrating that the majority of Fcgrt mRNA in the retina is
expressed by endothelial cells. However, Fcgrt mRNA was not
enriched to the same extent as Cdh5 mRNA, which could
suggest that some nonendothelial cells in the mouse retina also
express Fcgrt.
For the human RPE/choroid sample, we used a mechanical
fractionation method based on pipetting buffer over the
surface of the RPE/choroid plexus to peel the RPE cells. The
RPE marker RPE65 was approximately 50 times enriched in the
RPE fraction, demonstrating efficient separation of the two
fractions. FCGRT mRNA was increased about 2.5-fold in the
isolated RPE cells (Fig. 1F), suggesting that FCGRT mRNA is
expressed by RPE cells. Furthermore, the signal in the choroid
fraction suggests that also cells in the choroid plexus express
FCGRT mRNA.
Nonspecificity Immunohistochemistry Staining of
Anti-hFcRn Antibodies
In order to establish the spatial distribution of hFcRn by IHC,
we tested a panel of reagents reported to provide antigen-
specific staining patterns. To this end we used cryosections
from PFA-fixed tissue and cryosections from unfixed, snap-
frozen tissue, post-fixed on the slide with acetone. We tested
six different commercially available antibodies that have been
reported to be suitable for hFcRn detection by IHC.10,14,17 Two
antibodies (polyclonal rabbit anti-FCGRT, HPA012122 and
HPA015130) failed to provide any signal on cryosections from
human, mouse, or rat eyes with either fixation method (not
shown). A third antibody (mouse monoclonal 1G3) also failed
to stain human tissue (not shown). On rat tissue, this antibody
stained retinal blood vessels nonspecifically (Figs. 2A, 2B),
presumably due to cross-reactivity of secondary anti-mouse IgG
antibodies with endogenous rat IgG.
In contrast, two further antibodies (rabbit polyclonal H-275
and M-255) both revealed a very similar, strong staining on
human tissue in the choroid plexus, the ciliary body (shown
for M-255 in Figs. 2C, 2D) and large retinal vessels (not shown),
which was consistent with our qPCR expression data (Fig. 1).
On mouse tissue, these antibodies (H-275 and M-255) also
produced a similar result, staining the choroid, retinal vessels
(shown for M-255 in Fig. 2E) and the ciliary body (not shown).
However, positive staining appeared to be diffuse and not
associated with specific cell populations (Figs. 2C, 2D).
Furthermore, an identical staining pattern was observed for
eyes from Fcgrt knockout (Fcgrt/) mice with antibody M-255
(Fig. 2F) and antibody H-275 (not shown). We therefore
concluded that neither of these two polyclonal antibodies was
suitable for reliable FcRn detection of eye tissue by IHC.
Specific IHC Staining of FCGRT in Transgenic Mice
We also tested a mouse monoclonal anti-hFcRn antibody
(ADM31) that was generated by immunizing Fcgrt/ mice
with spleen cells from mice that overexpress human
FCGRT.15,18 The antibody is reported to react only with hFcRn
and not with the orthologous mouse heterodimer.15 In order to
further evaluate this antibody, we used human (h) FCGRT
transgenic mice (line 32) that lack the mouse Fcgrt gene
(hFCRN transgenic mice).13 Furthermore, to overcome the
problem of secondary anti-mouse antibodies cross-reacting
with endogenous mouse IgG, we directly conjugated ADM31
antibody with AlexaFluor 488. This did not result in a directly
observable staining. However, signal amplification via the use
of a rabbit antibody against AlexaFluor 488 and subsequent
detection with a donkey anti-rabbit IgG AlexaFluor 596-
conjugated antibody resulted in strong staining in tissues from
hFCGRT transgenic mice. The strongest signal was visible in
the ciliary body and choroid plexus, with weaker staining also
visible in the retinal vasculature (Figs. 3A, 3D, 3G, 3J, 3M, 3P).
Only acetone-fixed sections could be stained, whereas PFA-
fixed tissue did not yield any staining. Eye tissue from Fcgrt/
mice was not labeled (Figs. 3B, 3E, 3H, 3K, 3N, 3Q),
confirming the specificity of the ADM31 antibody. Tissue from
wild type Fcgrtþ/þmice was not labeled either (Figs. 3C, 3F, 3I,
3L, 3O, 3R), which was expected since the ADM31 antibody
does not bind mouse FcRn.
FcRn Immunohistochemistry of Human Eyes
Having established the specificity of the ADM31 antibody in
detecting hFcRn by IHC in hFCGRT transgenic mice, we used
this antibody to study the distribution of hFcRn on acetone-
fixed sections from human eyes. In this instance, we used
FIGURE 2. IG3 and M-255 antibodies fail to specifically detect FcRn by
immunohistochemistry. Immunohistochemistry with the mouse mono-
clonal IG3 antibody (anti-FcRn, red in [A]) appears the same as the
negative control with only secondary antibody (anti-mouse IgG, red in
[B]). The polyclonal rabbit M-255 antibody (anti-FcRn) provided
staining on human choroid (C) and ciliary body (D). However, a
similar staining pattern was obtained in choroid from wild-type (WT)
mice (E) and FcRn knockout (Fcgrt/) mice (F), suggesting
nonspecific activity of the M-255 antibody.
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rabbit anti-mouse IgG and AlexaFluor 596 donkey anti-rabbit
IgG to visualize ADM31 binding.
Prominent staining was found in the ciliary body (Figs. 4A–
C). The nonpigmented ciliary body epithelium was particularly
strongly labeled. In the pigmented ciliary body, the signal
seemed weaker (Figs. 4D–F), which may have been caused
partly through quenching of the fluorescent signal by the
pigment. At higher magnification the staining appeared
vesicular (Figs. 4G–I), consistent with the known cellular
location of FcRn in endosomes. Blood vessels in the ciliary
body were not stained (Figs. 4J–L). This was in contrast to our
findings in the transgenic mice, where blood vessels in the
ciliary body were strongly stained (Fig. 3A). In addition,
strongly labeled, isolated cells were detected in the ciliary body
stroma (Figs. 4J–L), which are most likely immune cells, such
as macrophages (see below).
In the choroid (Fig. 5) we also found strongly hFcRn
positive, single cells (arrowheads in Figs. 5A–I). They were
often in a perivascular location. In order to establish the
identity of these cells, we used a marker for resident
macrophages (Iba1).16 The acetone fixation (required for the
hFcRn staining) prevented colabeling with Iba1 and we
therefore used PFA-fixed adjacent sections. The distribution
of Iba-1 positive cells was similar and in some instances cells
could be detected in similar locations in both sections
(arrowheads in Figs. 5G–L).
FIGURE 3. hFcRn in hFCGRT-transgenic mouse eyes (red in [A–I, M–O] and white in [J–L, P–R]). Blood vessels have been stained with lectin (IB4,
green in [A–I,M–O]). Transgenic mice expressing human hFcRn are shown in (A, D, G, J,M, P); mice lacking Fcgrt are shown in (B, E, H, K, N, Q);
and wild-type mice are in (C, F, I, L, O, R). Ciliary body is shown in (A–C); retina and choroid in (D–F); retinal vasculature capillaries (arrowheads)
in (G–L) and choroid in (M–R). Arrows in (A–C) indicate blood vessels.
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Blood vessels were hFcRn positive in the choriocapillaris
(arrows in Figs. 5D–F), but larger vessels in Sattler’s and
Haller’s layer were negative (star in Figs. 5G–I). In the retinal
vasculature (Fig. 6), we found an inverse situation; here the
large vessels were hFcRn positive (Figs. 6A–F) but not
capillaries (Figs. 6M–O). As in the choroid, in the retina were
also numerous, strongly hFcRn-positive perivascular cells
(arrowheads in Figs. 6A–I, M–O). Iba1 immunohistochemistry
in an adjacent section (Figs. 6J–L) strongly suggests that these
perivascular cells are macrophages.
DISCUSSION
In this study we describe FcRn expression in three main
locations: the ciliary body epithelium, macrophages, and
endothelial cells of the choroid and retinal vasculature.
Our RT-qPCR analysis revealed similar expression of Fcgrt
mRNA in the RPE/choroid and the ciliary body/iris plexus in
four different species (rat, mouse, pig, and human). A further
commonality between rat, mouse, and pig was very low
expression in the cornea (human cornea was not measured).
These findings partially conflict with a previous study based on
semiquantitative PCR procedures that reported a complete
absence of Fcgrt mRNA in rat RPE/choroid, low levels in the
ciliary body/iris, and high levels in the cornea.10 The
discrepancies might be explained by the different methods
used to measure Fcgrt mRNA. Semiquantitative PCR can be
affected by differences in the efficiency of mRNA isolation,
reverse transcription, and loading volumes. We used qPCR
techniques and three separate internal standards (Actb, Gapdh,
and Ppia) to normalize our data, which should provide a more
accurate representation of gene expression.
Our RT-qPCR findings were largely confirmed by immuno-
histochemistry on human and transgenic mouse tissue. We
have gone to great lengths to ensure that our hFcRn
immunohistochemistry was specific. Surprisingly, the commer-
cially available antibodies we tested either provided no or
nonspecific signals. In contrast, specificity of the ADM31
FIGURE 4. FcRn expression in the human ciliary body. Fluorescent immunohistochemistry with ADM31 antibody visualizes the distribution of FcRn
(red in [A, D, G, J] and white in [B, E, H, K]) in the ciliary body. Blood vessels (stars in [J, K, L]) are labeled with lectin (UAE) in green (A, D, G, J).
Bright field images are shown in (C, F, I, L). Arrows in (D–F) indicate the nonpigmented ciliary epithelium. High magnification reveals a punctate
stain in nonpigmented ciliary epithelium (arrowheads in [G–I]). In the ciliary body stroma, strongly FcRn-positive cells can be detected (arrows in
[J–L]) but blood vessels (stars in [J–L]) are negative. Scale bars are 50 lm in (A), 20 lm in (D, J), and 10 lm in D.
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antibody for human hFcRn was clearly demonstrated in our
study by positive staining in hFCGRT transgenic mice and the
absence of staining in FcRn/ mice.
Expression of hFcRn in transgenic mice was highest in the
ciliary body epithelium and in the RPE/choroid plexus. This
matched our IHC and qPCR data from human tissue. The
transgene used for the generation of the transgenic mice was a
33-kb cosmid clone including the entire FCGRT gene
(approximately 11 kb) as well as 10 kb of 50 and 30 flanking
sequences, which is likely to confer good replication of
endogenous hFcRn expression. Ongoing studies indicate that
the tissue patterns of hFcRn expression determined by ADM31
are consistent with those generally expected in humans
(Roopenian et al; unpublished observations, 2013); however,
definition of the tissues sites of FCGRT expression in humans is
blurred by the issues raised above concerning the reliability of
many antibodies commonly used for detection. The differential
patterns of hFcRn observed in ciliary stromal vessels found in
human and transgenic mice using the highly specific antibody
ADM32 remains to be explained.
In human tissue, hFcRn immunohistochemistry and qPCR
data matched surprisingly well. Both readouts detected strong
expression in the ciliary body epithelium and in the RPE/
choroid and relatively low expression in the retina. This
consistency across different measurement techniques provides
further confidence into the reliability of our results.
FcRn has a known function in endothelial cells.5,19 Our
finding of FcRn-positive endothelial cells in the choriocapillaris
and large retinal vessels is consistent with this site of action.
However, capillaries in the retinal vasculature and large vessels
in the choroid lacked staining. In our study, it is not clear
whether the absence of staining in certain vessels is due to a
complete lack of expression or due to low expression levels
below the detection limit of our immunohistochemistry.
However, it has been shown previously that endothelial FcRn
expression can vary considerably in different vascular beds,5
underscoring the heterogeneity of the endothelium.
Immunohistochemistry on RPE of human tissue sections
was inconclusive. A previous study has reported FCGRT mRNA
in primary cultures of human RPE cells.20 Our qPCR data on
isolated human RPE cells (Fig. 1G) supports this finding.
However, on tissue sections, a potential FcRn immunohisto-
chemistry signal was below the detection limit and could not
be distinguished from autofluorescence in human RPE.
In contrast, we found very strong FcRn staining on many
single, isolated cells in the choroid and the ciliary body stroma
and in the retina. These cells were often found in a perivascular
location and are most likely monocytic antigen-presenting
cells, which are known to express high levels of FcRn.5,21 This
may be particularly relevant in AMD patients who are injected
with VEGF-blocking molecules containing an intact IgG-Fc
domain. AMD is known to be driven at least in part by
inflammatory components, such as macrophages,22–24 which
might influence the pharmacokinetics of IgG-Fc containing
molecules.
FcRn staining was also very strong in the ciliary body
epithelium, but the biological significance of FcRn at this site is
not clear. One of the main functions of the ciliary body is to
produce aqueous humor from blood. The concentration of IgG
in aqueous humor is more than 100 times lower than in
blood.25 FcRn in the ciliary body might therefore be
responsible for retaining IgG in the blood. It is also possible
that, like in endothelial cells, FcRn protects IgG from
degradation in ciliary body epithelium. In addition, FcRn might
FIGURE 5. FcRn expression in the human choroid. Fluorescent immunohistochemistry with ADM31 antibody visualizes the distribution of FcRn
(red in [A, D, G] and white in [B, E, H]) in the choroid. Macrophages (arrowheads) are labeled with Iba1 antibody (red) in (J) and (white) (K) in an
adjacent section. Blood vessels are labeled with lectin in green (A, D, G, J). Bright field images are shown in (C, F, I, L). Arrows in (D–F) indicate
FcRn-positive endothelial cells in the choriocapillaris. Large vessels (star in [G, H]) are FcRn negative. Scale bars are 50 lm in (A, G, J) and 20 lm in
(D).
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also mediate reverse transcytosis, the transport of IgG from the
CNS/retina into the blood stream. In the brain, this occurs in
the choroid plexus, where FcRn has been shown to be
expressed.5,17 It has been suggested that this process is
responsible for the rapid removal of therapeutic IgG injected
into the brain.26,27 A similar mechanism might also apply to the
ciliary body.
Several studies have shown prolonged reduction of VEGF in
the systemic circulation of patients after intravitreal injection
of bevacizumab (an anti-VEGF antibody containing an IgG-Fc
domain).28–31 This clearly demonstrates that intravitreally
injected IgG can cross the blood-retina barrier. In contrast,
systemic plasma concentrations of VEGF were not affected by
intravitreal ranibizumab (an anti-VEGF Fab fragment, lacking an
Fc domain).28,30 This could be explained by the different half-
lives in plasma of the two anti-VEGF agents.8,9 However, it is
also possible that FcRn in the eye might contribute to an IgG-Fc
specific transport mechanism from the eye into the periphery.
In summary, our study has shown that FcRn is expressed in
several locations in the eye where potential interactions
between FcRn and intravitreally injected molecules containing
IgG-Fc domains can occur, which might affect their local
distribution, half-life in the eye and transport into the
peripheral circulation.
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